This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1996 Jan 13;312(7023):121-2.

doi: 10.1136/bmj.312.7023.121a.

Guidelines for prescribing combined oral contraceptives

A M Mills, C L Wilkinson, D R Bromham, J Elias, K Fotherby, J Guillebaud, A Kubba, A Wade

PMID: 8555906
PMCID: PMC2349741
DOI: 10.1136/bmj.312.7023.121a

Guidelines for prescribing combined oral contraceptives

A M Mills et al. BMJ. 1996.

. 1996 Jan 13;312(7023):121-2.

doi: 10.1136/bmj.312.7023.121a.

Authors

A M Mills, C L Wilkinson, D R Bromham, J Elias, K Fotherby, J Guillebaud, A Kubba, A Wade

PMID: 8555906
PMCID: PMC2349741
DOI: 10.1136/bmj.312.7023.121a

No abstract available

PubMed Disclaimer

Comment in

Third generation oral contraception and venous thromboembolism.
McPherson K. McPherson K. BMJ. 1996 Jan 13;312(7023):68-9. doi: 10.1136/bmj.312.7023.68. BMJ. 1996. PMID: 8555921 Free PMC article. No abstract available.

Similar articles

What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
Meurer LN, Slawson JG. Meurer LN, et al. J Fam Pract. 2001 Feb;50(2):108. J Fam Pract. 2001. PMID: 11219554 No abstract available.
[Changed routines in connection with first prescription of oral contraceptives. Lower risk of venous thromboembolism with levonorgestrel preparations].
Milsom I, Odlind V, von Schoultz B, Ostlund I, Persson E. Milsom I, et al. Lakartidningen. 2002 Jan 10;99(1-2):10-2, 15. Lakartidningen. 2002. PMID: 11871161 Swedish. No abstract available.
Desogestrel, gestodene contraceptives may carry greater thromboembolic risk.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 1996 Feb 1;53(3):228. doi: 10.1093/ajhp/53.3.228a. Am J Health Syst Pharm. 1996. PMID: 8808016 No abstract available.
[Third-generation oral contraceptives--how big is the risk of venous thrombosis?].
Iversen OE. Iversen OE. Tidsskr Nor Laegeforen. 2004 Jun 3;124(11):1521-2. Tidsskr Nor Laegeforen. 2004. PMID: 15195157 Review. Norwegian. No abstract available.
Oral contraceptives and venous thromboembolism.
Speroff L. Speroff L. Int J Gynaecol Obstet. 1996 Jul;54(1):45-50. doi: 10.1016/0020-7292(96)02669-0. Int J Gynaecol Obstet. 1996. PMID: 8842817 Review.

See all similar articles

Cited by

Diane-35 (cyproterone acetate): safety concerns.
Wooltorton E. Wooltorton E. CMAJ. 2003 Feb 18;168(4):455-6. CMAJ. 2003. PMID: 12591790 Free PMC article. No abstract available.
How to communicate evidence to patients.
Freeman ALJ. Freeman ALJ. Drug Ther Bull. 2019 Aug;57(8):119-124. doi: 10.1136/dtb.2019.000008. Drug Ther Bull. 2019. PMID: 31345957 Free PMC article. Review. No abstract available.

References

1. BMJ. 1996 Jan 13;312(7023):88-90 - PubMed
1. BMJ. 1996 Jan 13;312(7023):83-8 - PubMed
1. Lancet. 1995 Dec 16;346(8990):1593-6 - PubMed
1. Lancet. 1995 Dec 16;346(8990):1589-93 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources